Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
Acute and mid-term results of phosphorylcholine-coated stents in primary coronary stenting for acute myocardial infarction
Autore:
Galli, M; Sommariva, L; Prati, F; Zerboni, S; Politi, A; Bonatti, R; Mameli, S; Butti, E; Pagano, A; Ferrari, G;
Indirizzi:
St Anna Hosp, Catheterizat Lab, Dept Cardiol, I-22100 Como, Italy St Anna Hosp Como Italy I-22100 t Lab, Dept Cardiol, I-22100 Como, Italy European Hosp, European Imaging Core Lab, Rome, Italy European Hosp RomeItaly n Hosp, European Imaging Core Lab, Rome, Italy
Titolo Testata:
CATHETERIZATION AND CARDIOVASCULAR INTERVENTIONS
fascicolo: 2, volume: 53, anno: 2001,
pagine: 182 - 187
SICI:
1522-1946(200106)53:2<182:AAMROP>2.0.ZU;2-W
Fonte:
ISI
Lingua:
ENG
Soggetto:
THROMBOLYTIC THERAPY; PRIMARY ANGIOPLASTY; ARTERY; MODEL; IMPLANTATION; TRIAL; PREDICTORS; SAFETY; DEATH;
Keywords:
clinical experience; coated coronary stent; acute myocardial infarction;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Clinical Medicine
Citazioni:
26
Recensione:
Indirizzi per estratti:
Indirizzo: Galli, M St Anna Hosp, Catheterizat Lab, Dept Cardiol, Via Napoleona 60, I-22100 Como, Italy St Anna Hosp Via Napoleona 60 Como Italy I-22100 100 Como, Italy
Citazione:
M. Galli et al., "Acute and mid-term results of phosphorylcholine-coated stents in primary coronary stenting for acute myocardial infarction", CATHET C IN, 53(2), 2001, pp. 182-187

Abstract

The aim of this pilot study was to evaluate the safety and efficacy of theBiodivYsio phosphorylcholine-coated stent in the primary treatment of acute myocardial infarction. The BiodivYsio stent (Biocompatible) is a balloon-expandable stent, laser etched from a 316 L stainless steel tube. This device is coated with phosphorylcholine, a synthetic, hemocompatible phospholipid polymer that has been shown in experimental studies to reduce platelet and protein adhesion to the surface of the metal. One hundred consecutive patients within 24 hr of symptoms of onset of acute MI, treated with primary PICA, were enrolled. After PICA, stenting was attempted in all eligible lesions (reference diameter greater than or equal to 2.5 mm; no bend lesion > 45 degrees). Poststenting regimens contained ticlopidine (500 mg/day) and aspirin (325 mg/day) and 6-12 hr of heparin infusion. Procedural success (TIMI greater than or equal to II and residual stenosis < 30%) was obtained in70/74 cases (95%). TIMI grade III was restored in 90% of cases. In the patient group with procedural success (70 cases), 70 BiodivYsio stents were placed. After stenting, diameter stenosis decreased from 96% +/- 11% to 22% +/- 12% (P < 0.01) and minimal luminal diameter increased from 0.13 +/- 0.29to 2.47 +/- 0.43 (P < 0.01). Nominal stent diameter was between 3.0 and 4.0 mm (mean, 3.5 +/- 0.4 mm). Stent length was between 11 and 28 mm (mean, 17 +/- 4.5 mm). Clinical follow-up was obtained in all patients; angiographic follow-up was performed in 65/70 (93%). No acute or subacute thrombosis was reported. Two in-hospital major adverse cardiac events (MACE) were reported due to a nontreated left main disease that required coronary artery bypass graft (CABG) surgery. At follow-up, MACE were found in 9 of 68 patients(13%), target lesion revascularization (TLR) in 6%, and CABG in the remaining 6%. Primary stenting with phosphorylcholine-coated stent leads to excellent short- and mid-term clinical outcomes and is associated with a restenosis rate of 12%. (C) 2001 Wiley-Liss, Inc.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 22/01/20 alle ore 12:22:44